What is Cyfuse Biomedical KK?
Cyfuse Biomedical KK operates at the intersection of biotechnology and advanced manufacturing, specializing in the development of cell-based innovations. The company is best known for its unique platform technologies, which include a sophisticated bio 3D printer and the creation of human 3D mini-liver constructs. These tools are instrumental in advancing drug discovery processes and providing researchers with high-fidelity models for testing therapeutic efficacy. By bridging the gap between laboratory research and clinical application, Cyfuse provides medical and pharmaceutical clients with unprecedented capabilities in tissue and organ engineering, ultimately aiming to provide patients with novel, life-saving treatment options.
How much funding has Cyfuse Biomedical KK raised?
Cyfuse Biomedical KK has raised a total of $27.3M across 3 funding rounds:
Series B
$12M
Private Equity
$3.4M
Series A
$11.9M
Series B (2015): $12M, investors not publicly disclosed
Private Equity (2017): $3.4M led by FUJIFILM Corporation
Series A (2018): $11.9M supported by Idinvest Partners, Elaia Partners, Partech International, and Brighteye Ventures
Key Investors in Cyfuse Biomedical KK
FUJIFILM Corporation
FUJIFILM Healthcare Americas Corporation is a medical manufacturing company providing diagnostic and enterprise imaging solutions designed to meet the evolving needs of healthcare across prevention, diagnosis, and treatment.
Idinvest Partners
Idinvest Partners is a mid-market private equity firm that finances and supports entrepreneurs at different stages of their business development, with a history dating back to 1997.
Partech International
Partech is a global investment firm that brings together capital, operational experience, and strategic support for entrepreneurs at seed, venture, and growth stages across multiple continents.
What's next for Cyfuse Biomedical KK?
With the support of its recent major strategic investment, Cyfuse Biomedical KK is well-positioned to expand its footprint in the global healthcare market. The company is expected to focus on scaling its bio-fabrication infrastructure and deepening its partnerships within the pharmaceutical industry to integrate its 3D tissue models into standard drug development workflows. As the firm continues to refine its regenerative medicine solutions, the focus will likely shift toward regulatory milestones and the broader adoption of its technology in clinical settings. This strategic roadmap ensures that Cyfuse remains at the forefront of the bio-tech revolution, leveraging its unique intellectual property to address critical gaps in modern medical science.
See full Cyfuse Biomedical KK company page
